https://scholars.lib.ntu.edu.tw/handle/123456789/502814
標題: | High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients | 作者: | Hsu K.-H. Huang Y.-H. Tseng J.-S. Chen K.-C. Ku W.-H. KANG-YI SU Chen J.J.W. HUEI-WEN CHEN SUNG-LIANG YU Yang T.-Y. Chang G.-C. |
公開日期: | 2019 | 卷: | 127 | 起(迄)頁: | 37-43 | 來源出版物: | Lung Cancer | 摘要: | Objectives: The main objective was to investigate the relationship between Programmed cell Death-ligand 1 (PD-L1) expression levels and the frequency of primary resistance to Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) in treatment na?ve advanced EGFR-mutant lung adenocarcinoma patients. Materials and methods: From 2012–2017, we enrolled advanced EGFR-mutant lung adenocarcinoma patients who displayed primary resistance to EGFR-TKI therapy, along with patients with disease control, and patients experiencing either stable disease or partial response to EGFR-TKI treatment. Results: Sixty-six patients were enrolled as the primary resistance group, while 57 patients were included as the disease control group. Fifteen-five (22.7%) patients had a PD-L1 Tumor Proportion Score (TPS) ≧50% in the primary resistance group, with only one patient (1.8%) having that score in the disease control group (P<0.001). Twenty (30.3%) patients had a PD-L1 ≧25% in the primary resistance group, with 2 (3.5%) patients having that level in the disease control group (P<0.001). Thirty (45.5%) patients had a PD-L1 ≧1% in the primary resistance group, with 7 (12.3%) patients at that level in the disease control group (P = 0.001). Patients with a PD-L1≧1% displayed a higher incidence of primary resistance to EGFR-TKIs than those with a PD-L1<1% (Odds Ratio (OR), 5.95; 95% Confidence Interval (CI), 2.35–15.05; P<0.001). The phenomenon existed still when the cutoff value was changed to both 25% (OR, 11.96; 95% CI, 2.65–53.87; P = 0.001) and 50% (OR, 16.47; 95% CI, 2.10–129.16; P = 0.008). The estimated median Progression-free Survival (PFS) rate was 7.3 months in patients with a PD-L1<1%, 2.1 months in patients with a PD-L1≧1%, 1.8 months in patients with a PD-L1≧25%, and 1.6 months in patients with a PD-L1≧50%. Conclusions: Treatment for advanced EGFR-mutant lung adenocarcinoma patients displaying a higher PD-L1 expression level experienced a higher frequency of primary resistance to EGFR-TKIs. ? 2018 Elsevier B.V. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/502814 | ISSN: | 0169-5002 | DOI: | 10.1016/j.lungcan.2018.11.021 | SDG/關鍵字: | afatinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; programmed death 1 ligand 1; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; PDCD1 protein, human; programmed death 1 receptor; protein kinase inhibitor; adult; aged; Article; cancer prognosis; cancer resistance; controlled study; female; gene mutation; human; lung adenocarcinoma; major clinical study; male; observational study; oncological parameters; overall survival; priority journal; progression free survival; retrospective study; Taiwan; Tumor Proportion Score; cancer staging; drug resistance; gene expression regulation; genetics; lung adenocarcinoma; lung tumor; metabolism; mutation; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Retrospective Studies |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。